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Pathogenesis of type 2 Diabetes Mellitus (DM) is often associated with chronic low-grade inflammation. This kind of 
inflammation is characterized by an increased level of pro-inflammatory cytokines such as tumor necrosis factor α (TNF-α), 
interleukin (IL)-6 and  IL-1β. From an immunological point of view, an inflammatory response is always followed by an anti-
inflammatory response as negative feedback to avoid excessive tissue damages. Regulatory T cells are a subset of cluster 
of differentiation (CD)4+ T cells that have the function to maintain peripheral tolerance and suppress immune response. 
This review would discuss the impaired function of regulatory T cells in type 2 DM. DM is a group of metabolic diseases 
characterized by hyperglycemia due to a defect of insulin secretion or a combination of insulin resistance and relative 
insulin deficiency. Chronic low-grade inflammation has been known as a key factor in the development of insulin resistance. 
Regulatory T cells (Treg cells) action through contact and non-contact inhibition could suppress inflammatory response 
in innate and adaptive immune systems. In type 2 DM, the proportion and function of CD4+CD25+Foxp3+ and CD4+CD25+ 
regulatory T cell decreases due to the reduced number of Treg cells and the Treg cells depletion contributes to metabolic 
conditions such as insulin resistance. Moreover, Treg cells are more susceptible to apoptosis, the ability of Treg cells to 
produce anti-inflammatory cytokines such as transforming growth factor β (TGF-β) and IL-10 decreases, and there is an 
imbalance between the proportion of Th1/Th17 cells and Treg cells. This inadequate anti-inflammatory response gives rise 
to the chronic low-grade inflammatory condition in type 2 DM.
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Introduction
Every year, the prevalence of diabetes mellitus (DM) keeps 
increasing. Based on International Diabetes Federation, in 
2017, this disease affected 415 million people worldwide 
and it is estimated that the prevalence will increase to 
642 million in 2045.1 Based on the data from Indonesian 
Basic Health Research (Riset Kesehatan Dasar/Riskesdas) 
in 2013, the number of DM patients were 6.9% for people 
over 15 years old, and 90% of them were type 2 DM.2 The 
fatality rate of this disease and its complication was on the 
third after stroke and acute myocardial infarction.3
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 DM is characterized by a group of metabolic diseases, 
including hyperglycemia due to the defect of insulin 
secretion or the combination of insulin resistance and 
relative insulin deficiency.4 Insulin resistance is a condition 
characterized by insulin-sensitive tissues, including skeletal 
muscle, adipose, and liver tissues are no longer sensitive to 
insulin.5
 Inflammation is often correlated with pathomechanism 
of type 2 DM, such as glucotoxicity, lipotoxicity, 
oxidative stress, and endoplasmic reticulum stress.6 Those 
mechanisms are the result of various stimuli, including 
physical inactivity, smoking, sedentary lifestyle, obesity, 
genetic and environmental factor. Those stimuli could 
activate C Jun N-terminal kinase (JNK) pathway and 
inhibitory kappa B kinases (IκKB) pathways that eventually 
trigger the activation of immune system.7 In addition, those 
stimuli could increase the level of systemic inflammatory 
mediators secreted by other tissues. These persistent and 
systematic changes would induce chronic low-grade 
inflammation. Other studies showed that this inflammation 
could be a leading factor to insulin resistance, β pancreatic 
cells dysfunction, and eventually type 2 DM.8
 From immunology's point of view, chronic low-
grade inflammation in type 2 DM is interesting. Every 
inflammatory stimulus would always be followed by an 
anti-inflammatory response as negative feedback.9 The goal 
of this feedback mechanism is attenuating immune response 
after antigen diminished and preventing tissue injury due 
to overexpression of immune response. On the other hands, 
there are some hypotheses indicate that the chronic low-
grade inflammation is not strong enough to elicit anti-
inflammatory activity.8
 Many studies showed the relationship between type 
2 DM and the level of the pro-inflammatory mediators 
such as tumor necrosis factor α (TNF-α), interleukin (IL)-
6, and IL-1β.10 However, the relationship between the anti-
inflammatory response and their mechanisms contributing 
to this disease was less explored.
 Regulatory T cells (Treg cells) are cluster of 
differentiation (CD)4+ T cell subset that has the function to 
maintain peripheral tolerance and suppress adaptive immune 
responses by secreting anti-inflammatory cytokines, such as 
transforming growth factor β (TGF-β), IL-10 and IL-35.11 
Previous studies demonstrated that CD4+CD25+Treg and 
CD4+CD25+Foxp3+ Treg cells elicited immune tolerance 
to self-antigen via contact and non-contact inhibition.11 
It was believed that the imbalance between inflammatory 
and anti-inflammatory response was the key factor in the 
development of type 2 DM.12 Therefore, in this paper, we 
would discuss the anti-inflammatory role of regulatory T 
cells in type 2 DM.
Diabetes Mellitus
DM is a group of metabolic diseases characterized by 
hyperglycemia resulting from the defect of insulin secretion 
or the combination of insulin resistance and relative insulin 
deficiency.4,13,14 Based on American Diabetes Association, 
DM is divided into 4 categories, which are type 1 DM caused 
by autoimmune β cell destruction, type 2 DM caused by a 
progressive loss of insulin secretion and insulin resistance, 
and gestational DM diagnosed in the last term of pregnancy, 
and other specific types of diabetes due to other causes.13,14
The Role of Inflammation in Insulin Resistance 
Insulin Functions
Insulin is a pleiotropic peptide hormone that has various 
functions, such as transporting nutrients into the cells, 
regulating genes expression, influencing enzymatic 
activities, and regulating energy balance via its action in the 
arcuate nucleus.15 Nonetheless, the main function of insulin 
is inducing intra-cellular glucose transport in insulin-
sensitive tissues.16
Insulin Signalling Pathway
Insulin signaling is a complex signaling cascade from the 
insulin receptor, involving 2 major pathways.17 The first 
pathway is phosphatidylinositol-3-kinase (PI3K) AKT 
which responsible for glucose uptake and suppression of 
gluconeogenesis. The second pathway is Ras mitogen-
activated protein kinase (MAPK) which mediates gene 
expression and regulates cell differentiation and growth.17 
The common intermediate of both pathways is insulin 
receptor substrate (IRS).17 Activation of insulin receptor 
leads to tyrosine phosphorylation of IRS, thus initiating 
signal transduction. 
 In the skeletal muscle, insulin induces glucose 
uptake by stimulating glucose transporter type 4 (GLUT4) 
translocation into the membrane. Disruption of this insulin 
signaling leads to the reduction of glucose uptake.15,16 In 
the liver, insulin inhibits the expression of gluconeogenic 
enzymes, hence disruption of this signalling would induce 
the production of hepatic glucose. In adipose tissue, insulin 
decreases lipase-sensitive hormones activities in order to 
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inhibit free fatty acid (FFA) moving out from adipocytes.16 
The increased FFA level in circulation would induce the 
reduction of insulin sensitivity in skeletal muscles due to the 
increasing of intermediate lipids, such as fatty acyl Co-a and 
ceramides. These intermediate lipids would activate serine/
threonine kinase and protein kinase C-θ (PKC-θ) leading to 
the inhibition of insulin signal cascade.15,16
Pathogenesis of Insulin Resistance
Insulin resistance plays a pivotal role in etiology and 
pathogenesis of type 2 DM. The capability of IRS, 
particularly IRS1 to regenerate signal is diminished if serine 
307 is phosphorylated. IκKB from NFκB pathway and 
JNK1 from JNK/AP-1 pathway are the most common serine 
kinases that phosphorylate serine 307.17 Activation of those 
pathways lead to insulin resistance.
 The development of insulin resistance is associated 
with chronic low-grade inflammatory response induced by 
pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α, 
chemokines and adipokines.15 In pancreatic β cells, chronic 
exposure of pro-inflammatory mediators also stimulates 
a cascade of signal protein that inhibits the activation of 
insulin receptor.15
 The most abundant pro-inflammatory cytokines 
involved in NFκB and JNK/AP-1 pathways are TNF-α, 
IL-1β and IL-6.10,15,17 TNF-α is pro-inflammatory cytokines 
secreted by monocytes and macrophages. This cytokine 
has various biological effects, such as lipid metabolism, 
blood coagulation, and endothelial function.15 TNF α binds 
to cytokine receptor which further induces the activation 
of transcriptional pathway including NFκB and JNK/AP-
1. After NFκB and JNK/AP-1 activated, these pathways 
would phosphorylate serine 307 on IRS1 that lead to insulin 
resistance.17
 IL-1β is a major proinflammatory cytokine that has a 
crucial role to regulate the expression of other cytokines, 
chemokines, and adipokines through the involvement of 
various transcriptional mediated pathways.15 This cytokine 
binds to IL-1 receptor type 1 (IL-1R1) and reduces the 
expression of IRS-1. Moreover, in β cells of pancreatic islet, 
it impairs insulin secretion.15
 Beside those mechanisms above, pro-inflammatory 
cytokines, FFA and oxidative stress could activate 
expression of Nos2, a gene that encodes  inducible nitric 
oxide synthase (iNOS). In the insulin signaling pathway, 
nitric oxide (NO) has the ability to reduce AKT activity 
via s-nitrosylation of cysteine residue. Moreover, increased 
level of NO could cause degradation of IRS1 in cultured 
skeletal muscle cells.18 Therefore, increased iNOS activity 
plays an important role in insulin action in skeletal muscle 
and β cells functions.17,18
 In obesity, the expansion of adipose tissue leads 
to adipocyte hypertrophy and reduce oxygen supply to 
adipocytes that cause hypoxia. Hypoxia of adipose tissue 
could activate the inflammatory response by producing pro-
inflammatory mediators such as TNF-α, IL-6, and matrix 
metalloproteinase (MMP).18 These pro-inflammatory 
mediators would attract macrophages infiltration to the 
extracellular matrix. Macrophages could digest and store 
lipid as atherosclerotic foam cell that also produces TNF-α 
that eventually exaggerate the inflammatory condition. 
Moreover, in adipose tissue, macrophages could express a 
large amount of NOS2 and IL-6 that have a contribution to 
insulin resistance.18
Treg Cell
Treg cells are CD4+ T cells that express CD25, an α-chain 
IL-2 receptor, and Foxp3, a transcriptional factor for 
Treg cells differentiation.19 Therefore, Treg cell could be 
recognized by the expression of CD4+, CD25+, and Foxp3+, 
although not all of the Treg cells express those receptors 
and transcriptional factor. Most of Treg cells maturation 
take place in thymus and they are called natural Treg 
cells (nTreg), meanwhile, the others develop in peripheral 
lymphoid organs due to antigen recognition, so they are 
known as inducible Treg (iTreg).20
 Treg cells have the various functions on controlling 
immune response in the body, such as preventing 
autoimmune disease, inducing immunologic tolerance 
to self-antigens, inducing immune tolerance to fetus in 
pregnant women, repressing immune pathologic response 
that induced by pathogen, as a feedback mechanism from 
immune response, protecting normal flora in gut system, 
and preventing overactivity of effector T cells that lead to 
diseases.20
 The existence and function of Treg cells depend on IL-
2.20 IL-2 is an important key for Foxp3 transcription in the 
thymus as well as peripheral lymphoid organs. IL-2 promotes 
the expression of Foxp3 by binding transcriptional factor 
signal transducer and activator of transcription (STAT)-5 
to Foxp3 promoter and Treg-specific demethylated region 
(TSDR), an enhancer for Foxp3 gene (Figure 1).20 IL-2, 
accompanied by TGF-β could induce the polarization of 
naïve CD4+ T cell to Foxp3+ iTreg cell.21
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 The cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4) is an inhibitory receptor on the surface of Treg 
cells.21 The function of this receptor is terminating effector 
T cell activity and mediating the suppressive action of 
Treg cells. In the Treg cell, the expression of CTLA-4 is 
regulated by Foxp3. CTLA-4 acts by blocking and removing 
B7 (CD80 and 86) molecules from antigen presenting 
cells (APC) surface, thereby reducing co-stimulation and 
preventing the activation of T cells.21 It is still debatable how 
T cells choose CD28 or CTLA-4. However, there is a fact 
that CTLA-4 affinity to B7 molecule is higher than CD28. 
When APC is presenting self-antigen, it expresses the low 
level of B7 molecules, so these molecules eventually bind 
to CTLA-4 and they would inhibit the immune response. On 
the contrary, in pathogenic infection, APC would express 
the high level of B7 molecules, therefore CD28 would bind 
to B7 molecules, and induce immune response.21
Suppressive Actions of Regulatory T Cells 
Treg cells could suppress immune response through 3 
mechanisms, which are non-contact inhibition, contact 
inhibition, and competition for IL-2 between effector T cells 
and Treg cells.22,23
Figure 1. Molecular mechanism 
for Foxp3 gene transcription.
 During non-contact inhibition, both suppressive 
cytokines TGF-β and IL-10 are the most important players 
(Figure 2).23 TGF-β is not only produced by Treg cells but 
also produced by other cell types, like APCs after activated 
by Treg cells.23 TGF-β as membrane-bound cytokine could 
induce effector T cells to respond Tregs action, increase 
the expression of Foxp3 in Treg cell, and other suppressive 
actions that have a contribution to T cell differentiation to 
Treg cell.24 IL-10 is a potent anti-inflammatory cytokine 
that has the ability to inhibit pro-inflammatory cytokines 
production, such as interferon (IFN)-γ, TNF-α, IL-1β and 
IL-6. IL-10 could also prevent maturation of dendritic cell 
(DC) via inhibiting IL-12 expression.25 Moreover, IL-10 
could suppress the expression of major histocompatibility 
complex (MHC) class II and co-stimulatory molecules B7 
in APCs.25,26
 Suppressive activity of Treg cells could be carried out 
by the mechanism of contact inhibition. It has been proven 
that Treg cells are unable to suppress the proliferation 
of effector T cell when both are separated by the semi-
permeable membrane.27 During this action, Treg cells could 
eliminate effector T cells by secreting granzyme or perforin, 
and sending negative signal to disrupt the metabolism 
of effector T cells through increased intracellular cyclic 
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Figure 2. Mechanisms of non-contact inhibition by IL-10 and TGF-β secreted by Treg cells.
adenosine monophosphate (AMP), which induces the 
inhibition of T cells proliferation, suppresses the production 
of IL-2, IFN-γ, and protein kinase A, and also activates 
transcription repressor inducible cAMP early repressor 
(ICER) and increases the production of pericellular 
adenosine that catalyzed by CD39 and CD73 in Treg cells. 
Adenosine would suppress the proliferation and cytokines 
production of effector T cells.21,24,27
 Figure 3 shows mechanisms of Treg cell suppresses 
effector T cell and dendritic cell. Activated Treg cells could 
affect APCs function by suppressing the expression of B7 
molecules and stimulating DCs to express indoleamine 
2,3-dioxygenase (IDO). IDO would catalyze the conversion 
of tryptophan, an essential amino acids to kynurenine which 
is toxic to T cells. Both mechanisms depend on CTLA-4 
in Treg cells which binds to B7 molecules in APCs.24,28 In 
addition, Treg cells could also be activated by the small 
number of antigens presented by immature DCs that express 
low B7 molecules.27 Activated Treg cells could increase 
the expression of lymphocyte function-associated antigen 
1 (LFA-1), and eventually, suppress the expression of B7 
molecules in DCs to below the level needed for activation 
and expansion of effector T cells.24,27 Foxp3+ Treg cells have 
ability to suppress plasmacytoid DCs (pDCs) that express 
low level of B7 molecules.27
 Another Treg suppression mechanism is the 
competition in consuming IL-2.28 As it is known that effector 
T cells, naïve, and effector T cells need IL-2 to proliferate 
and differentiate. Treg cells express CD25 which has high 
affinity to IL-2. Moreover, expression of CD25 allows Treg 
cells consume more IL-2 than effector T cells. Therefore, 
this competition induces apoptosis in the effector T cells that 
lack of IL-2.28 Apoptosis in the effector T cells is mediated 
by B-cell lymphoma 2 (Bcl-2) interacting mediator (BIM).21
Regulatory T Cells in Type 2 DM
Treg cells could inhibit the inflammatory response through 
the various pathways, such as increasing the secretion of anti-
inflammatory cytokines, modulating microenvironment, 
and changing the expression of cell receptors.28 The balance 
between T helper (Th)1 and Th17 cells as pro-inflammatory 
cells and Treg cells is very vital to maintain homeostasis 
and control tissue damages due to excessive inflammatory 
response.29
 In peripheral blood of type 2 DM patients, it was found 
that the proportion of CD4+ T cells were not different from the 
healthy controls, but the proportion of CD4+CD25+Foxp3+ 
and CD4+CD25+ Treg cells decreased significantly. The 
proportion of CD4+CD25- T cells which would develop into 
other cell types did not show any differences.30
 Treg cells circulate in peripheral blood including 
nTreg and iTreg cells. In type 2 DM patients, it was 
found that the percentage of nTreg cells did not decrease 
significantly, meanwhile the percentage of iTreg cells 
dropped dramatically, thus indicated that the decrease in the 
number and percentage of Treg cells in peripheral blood was 
caused by component of the peripheral immune system and 
it was not controlled by thymus.30
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Figure 3. Mechanisms of Treg cell suppresses effector T cell and dendritic cell. (a): Treg cell expresses CD25 which has 
high affinity to IL-2, thus makes effector T cell is starvation and leads to cell death; (b): Granzyme and perforin secreted by 
Treg cell act on effector cell and cause apoptosis; (c): cAMP gets into effector cell trough gap junction and inhibits expression 
of proinflammatory cytokines and T cell proliferation; (d): CD73/CD39 on the surface of Treg cells converts ATP to adenine, 
which binds to A2A receptor on the effector T cells and inhibit the immune response; (e): CTLA-4 on the surface of Treg cells 
binds to B7 molecules on dendritic cell then promotes IDO secretion, IDO would inhibit interferon γ and degrade tryptophan 
to kynurenine; kynurenine and  depletion of tryptophan lead to effector cell apoptosis.
 Treg cells in type 2 DM were found to be susceptible 
to apoptosis than Treg cells in healthy controls. The 
susceptibility of cells to apoptosis is controlled by the 
expression of Bcl-2 and Bax protein. The ratio of Bcl-2/
Bax in Treg cells in type 2 DM is significantly lower than 
normal.30 Therefore, this might be one of the other factors 
that cause fewer number of Treg cells in type 2 DM. In 
addition, dyslipidemia could be another factor that affects 
the number of Treg cells.30
 CD39 is an ectoenzyme expressed in Treg cells.31 The 
function of CD39 is hydrolyzed adenosine triphosphate 
(ATP) and adenosine diphosphate (ADP) to AMP which is 
then converted by CD73 to adenosine metabolite that could 
suppress effector T cells.31,32 CD39 is also related to the 
stability and suppressive function of Foxp3+ Treg cells. The 
expression of programmed death-ligand 1 (PD-L1), CD25, 
CTLA-4, and IL-10 are higher on the surface of CD39hiTreg 
cells compared to CD39lowTreg cells.32,33 A study reported 
that the number of CD39hiTreg cells were lower under 
the chronic inflammatory conditions such as obesity and 
type 2 DM.32 Moreover, the percentages of CD39+ cells 
and CD39+CD19+ cells were significantly associated with 
HbA1c and fasting plasma glucose levels.34 Therefore, those 
might prove that the suppressive function of Treg cells is 
impaired in type 2 DM.
 T lymphocytes could mediate mechanisms of 
immunopathology in type 2 DM through various organs 
directly. The infiltration of T cells in the kidney is related 
to the development of diabetic nephropathy in type 2 DM.35 
This condition could be aggravated by the accumulation 
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of macrophages and their proinflammatory cytokines, 
such as IFN-γ and IL-1β. A study conducted in diabetic 
nephropathy db/db mice revealed Treg cells might 
improve nephropathy.35 Treg cells depletion through the 
administration of anti-CD25 would exacerbate nephropathy, 
renal dysfunction, and leukocytes infiltration of the 
kidney. Moreover, administration of Treg cells in diabetic 
nephropathy db/db mice could alleviate renal function and 
dampen nephropathy.35
 As discussed previously, both IL-10 and TGF-β are 
potent anti-inflammatory cytokines produced by Treg 
cells. IL-10 could suppress proliferative activity in T cells, 
whereas TGF-β maintains the expression of Foxp3 in Treg 
cells to improve immunosuppressive function.23 In type 2 
DM, the serum level of IL-10 decreases, but the level of 
TGF-β increases especially in the patient with diabetic 
complications such as retinopathy and nephropathy.36
Association between Treg Cells and Th1/Th17 
Cells in Type 2 DM
During activation, naïve CD4+ T cells would differentiate 
to Th1, Th2, T Th17, or Treg cells and those depend on 
the presence of certain cytokines in the microenvironment. 
Naïve T cells will differentiate to Th1 cell if IL-12 presents. 
Those cells will become Th2 cells if IL-4 presents. They will 
differentiate to Treg cells if there is TGF-β. The last, naïve 
T cells will become Th17 cells if TGF-β and IL-6 present.24
 In a study, it was revealed that the number of Th1 
and Th17 cells in the peripheral blood cells of type 2 DM 
was higher.30 However, the ratio of Th17/Th1 cells in 
type 2 DM was not different from healthy subjects. Th17 
cells differentiation was correlated with the number of 
CD4+CD25+Foxp3+ Treg cells in peripheral blood cells and 
the serum level of IL-6, IL-10 and TGF-β. Although IL-17 
level did not differ between type 2 DM and controls, the 
presence of IL-17 indicated that Th17 cells involved in the 
pathogenesis of type 2 DM.30 An inflammatory condition in 
type 2 DM causes imbalance between Th1, Th17 and Treg 
cells population, as seen in Figure 4.
 The decrease was seen in the ratio of CD4+ CD25+ 
Treg/Th1 cells and CD4+ CD25+ Treg/Th17 cells. The 
similar result was also seen in the ratio CD4+ CD25+ Foxp3+ 
Treg/Th1 cells and CD4+CD25+Foxp3+ Treg/Th17 cells.31 
Those ratios were not affected by the duration of DM and 
the serum level of HbA1c.31 This suggested that the duration 
and severity of hyperglycemia did not affect the balance 
between Treg, Th1 and Th17 cells. 
Figure 4. Inflammatory condition in type 2 DM causes imbalance between Th1, Th17 and Treg cells population. 
Futhermore, Treg cells undergo metabolic disruption, such as decreasing Bcl2/Bax ratio that leads to increase susceptibility to 
apoptosis, decreasing the expression of CD39 that disrupts the stability of Foxp3 gene, decreasing the expression of CTLA-4, 
PD-L1, CD25, and IL-10 secreation. Those would cause the suppression functions of Treg cells become impaired.
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Another study revealed that the imbalance in the population 
of CD4+ cells subset had occurred since the early stages of 
DM and far before the onset of complications.30 In addition, 
the percentage of CD4+CD25+ Treg cells in type 2 DM 
with microvascular complication was lower compared to 
the healthy subjects and type 2 DM with macrovascular 
complication meanwhile, the percentage of Th1 and Th17 
cells increased in type 2 DM patients with or without any 
complications.30
Conclusion
Inflammatory condition in type 2 DM affects the proportion 
of T cell subsets, which characterized by increasing the 
number of Th1 and Th17 cells, while the number of Treg 
cells decreases. The number and function of Treg cells 
decline due to various things, including the percentage of 
iTreg cells decreases that indicates the defects in peripheral 
immune system, increased the ratio of Bcl-2/Bax in Treg 
cells indicates that Tregs cells are more susceptible to 
apoptosis, decreased the suppressive function of Treg 
cells as shown in mechanism of contact and non contact 
inhibition, and  increased the level of pro-inflammatory 
cytokines that induce naïve T cell differentiation into Th1 
and Th17 cells. This disturbance is likely happened since 
the early stage of DM or insulin resistance stage and far 
before the onset of complications.
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